Clinical Trial Update: PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT [NA]

View source ↗

Summary

Clinical trial evaluating the combination of a PD-1 inhibitor, azacitidine, and low-dose donor lymphocyte infusion for relapse of acute myeloid leukemia after a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Donor Lymphocyte Infusion
• PD-1 inhibitor

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia | NA | Status: RECRUITING